Study of Immune Response in Chronic Histiocytic Intervillositis and Its Role in Pregnancy Complications

What this Trial Is About

Chronic histiocytic intervillositis CHI is a rare pregnancy condition affecting about 5 in 10,000 pregnancies. It involves inflammatory lesions in the placenta that can cause serious pregnancy problems like growth delays, fetal death, and miscarriage. The exact causes of CHI are not well understood, and current treatments are challenging and often ineffective. Recent research suggests an immune response against the fetus may be involved, similar to organ transplant rejection, and this study aims to explore this further and predict risks of fetal loss. The study involves three groups patients with CHI, patients with antiphospholipid syndrome APS, and women with normal pregnancies. Researchers will collect blood samples from the parents, saliva or blood from their children, and placental tissue at childbirth. These biological samples will help analyze immune responses and placental changes related to CHI and other pregnancy outcomes. Participants will provide samples at inclusion and childbirth, which will be examined for immune markers, antibody levels, and placental changes. The main focus is to determine how often CHI shows signs of immune rejection and to study links between antibody levels and pregnancy complications like growth retardation and fetal death. The study will measure various immune and placental markers up to six months after sample collection to better understand CHIs mechanisms.

Exploration of Allograft Humoral Rejection in Chronic Histiocytic Intervillositis